C-reactive Protein Is Associated With Prevalence of the Metabolic Syndrome, Hypertension, and Diabetes Mellitus in US Adults

Angiology

Volumn 69, Issue 5, 2018, Pages 438-442

  Mazidi, Mohsen ^a   Toth, Peter P ^b,c   Banach, Maciej ^d,e  

^a INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^b CGH Medical Center   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

diabetes mellitus; high sensitivity C reactive protein; metabolic syndrome

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; UNITED STATES; WAIST CIRCUMFERENCE; BLOOD; CROSS-SECTIONAL STUDY; HYPERTENSION; METABOLISM; MIDDLE AGED; NUTRITION;

ADULT; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME; MIDDLE AGED; NUTRITION SURVEYS; PREVALENCE; UNITED STATES;

EID: 85040174760     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319717729288     Document Type: Article

References (36)

1. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Ann Rev Nutr. 2005;25(7):391–406.
2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428.
3. Ertek S, Banach M. Editorial: the changing face of metabolic syndrome and its components in the light of current knowledge. Curr Vasc Pharmacol. 2014;12(4):549–552.
4. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497.
5. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28(11):2745–2749.
6. Mazidi M, Pennathur S, Afshinnia F. Link of dietary patterns with metabolic syndrome: analysis of the National Health and Nutrition Examination Survey. Nutr Diabetes. 2017;7(3):e255.
7. Lakka HM, Laaksonen DE, Lakka TA. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709–2716.
8. Rizzo M, Barylski M, Rizvi AA, Montalto G, Mikhailidis DP, Banach M. Combined dyslipidemia: Should the focus be LDL cholesterol or atherogenic dyslipidemia? Curr Pharm Des. 2013;19(21):3858–3868.
9. Mazidi M, Gao HK, Vatanparast H, Kengne AP. Impact of the dietary fatty acid intake on C-reactive protein levels in US adults. Medicine (Baltimore). 2017;96(7):e5736.
10. Mazidi M, Heidari-Bakavoli A, Khayyatzadeh SS. Serum hs-CRP varies with dietary cholesterol, but not dietary fatty acid intake in individuals free of any history of cardiovascular disease. Eur J Clin Nutr. 2016;70(12):1454–1457.
11. Mazidi M, Kengne AP, P Mikhailidis D, F Cicero A, Banach M. Effects of selected dietary constituents on high-sensitivity C-reactive protein levels in U.S. adults. Ann Med. 2017. doi: 10.1080/07853890.2017.1325967
12. Mazidi M, Karimi E, Rezaie P, Ferns G. Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. J Diabetes Complications. 2016;31(7):1237–1242.
13. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol. 2009;20(3):182–189.
14. Zaki ME, El-Bassyouni HT, El-Gammal M, Kamal S. Indicators of the metabolic syndrome in obese adolescents. Arch Med Sci. 2015;11(1):92–98.
15. Mazidi M, Rezaie P, Ferns GA, Vatanparast H. Impact of probiotic administration on serum C-reactive protein concentrations: systematic review and meta-analysis of randomized control trials. Nutrients. 2017;9(1).
16. Mazidi M, Kengne AP. Nutrient patterns and their relationship with general and central obesity in US adults [Published online March 10, 2017]. Eur J Clin Invest. doi:10.1111/eci.12745
17. Mazidi M, Kengne AP, Banach M. Mineral and vitamins consumption is associated with longer telomeres among US adults. Pol Arch Med Wewn. 2017;127(2):87–90.
18. Mazidi M, Kengne AP, Sahebkar A, Banach M. Telomere length is associated with cardiometabolic factors in US adults [Published online January 1, 2017]. Angiology. doi: 10.1177/0003319717712860
19. http://www.cdc.gov/NCHS/data/nhanes/nhanes_09_10/CRP_F_met.pdf. Accessed June 12, 2017.
20. Grundy SM, Brewer HB, JrCleeman JI, Smith SC, JrLenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433–438.
21. Mazidi M, Michos ED, Banach M. The association of telomere length and serum 25-hydroxyvitamin D levels in US adults: The National health and nutrition examination survey. Arch Med Sci. 2017;13(1):61–65.
22. Statistics. NCfH. Analytic and reporting guidelines. http://www.cdc.gov/nchs/data/nhanes/%20nhanes%2003%2004/nhanes%20analytic%20guidelines%20dec%202005.pdf. Accessed June 12, 2017.
23. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109(23):2818–2825.
24. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103(13):1813–1818.
25. Mazidi M, Karimi E, Rezaie P, Ferns GA. Effects of conjugated linoleic acid supplementation on serum C-reactive protein: a systematic review and meta-analysis of randomized controlled trials [Published online May 29, 2017]. Cardiovasc Ther. doi: 10.1111/1755-5922.12275
26. Huffman FG, Gomez GP, Zarini GG. Metabolic syndrome and high-sensitivity C-reactive protein in Cubans. Ethn Dis. 2009;19(2):115–120.
27. Kang ES, Kim HJ, Ahn CW. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res Clin Pract. 2005;69(2):151–159.
28. Yudkin JS, Juhan-Vague I, Hawe E. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism. 2004;53(7):852–857.
29. Voils SA, Cooper-DeHoff RM. Association between high sensitivity C-reactive protein and metabolic syndrome in subjects completing the National Health and Nutrition Examination Survey (NHANES) 2009-10. Diabetes Metab Syndr. 2014;8(2):88–90.
30. Vongpatanasin W, Thomas GD, Schwartz R. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation. 2007;115(8):1020–1028.
31. Szmitko PE, Verma S. C-reactive protein and reendothelialization: NO involvement. Circ Res. 2007;100(10):1405–1407.
32. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52(3):415–472.
33. D’Alessandris C, Lauro R, Presta I, Sesti G. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia. 2007;50(4):840–849.
34. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–843.
35. Festa A, D’Agostino R, JrHoward G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 2000;102(1):42–47.
36. Festa A, D’Agostino R, JrTracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51(4):1131–1137.